Recently, GATA2 is proved to be required for the survival of RAS pathway mutated non-small cell lung cancer (NSCLC) cells [23], and it has identified that GATA2 as a regulator of chemotherapy resistance and tumorigenicity in lethal prostate cancer through experimental models and clinical databases [24]. The gene discussed is GATA2; the disease is Familial prostate cancer.